Recurrent glioblastoma: A fresh look at current therapies and emerging novel approaches

Seminars in Oncology

Volumn 38, Issue SUPPL. 4, 2011, Pages

  Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CILENGITIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; INIPARIB; ISOCITRATE DEHYDROGENASE; LENALIDOMIDE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLAPARIB; PENICILLAMINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VELIPARIB; VINCRISTINE; XL 184;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; METRONOMIC CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN;

EID: 80855133497     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.09.008     Document Type: Conference Paper

References (117)

1. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007 www.cbtrus.org/reports/ reports.html 2011 Accessed August 19, 2011
2. N. Sanai, and M.S. Berger Glioma extent of resection and its impact on patient outcome Neurosurgery 62 2008 753 764
3. E.A. Neuwelt, B. Bauer, and C. Fahlke Engaging neuroscience to advance translational research in brain barrier biology Nat Rev Neurosci 12 2011 169 182
4. P.Y. Wen, D. Schiff, S. Kesari, J. Drappatz, D.C. Gigas, and L. Doherty Medical management of patients with brain tumors J Neurooncol 80 2006 313 332 (Pubitemid 44782910)
5. K.Y. Yap, W.K. Chui, and A. Chan Drug interactions between chemotherapeutic regimens and antiepileptics Clin Ther 30 2008 1385 1407
6. A.G. Mammoser, D.E. Blas-Boria, and M.R. Gilbert Novel clinical trials in neuro-oncology Clin Invest 1 2011 781 794
7. National Comprehensive Cancer Network NCCN Guidelines Version 2.2011: Central Nervous System Cancers www.nccn.org Accessed August 16, 2011
8. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
9. F.G. Barker 2nd, S.M. Chang, and P.H. Gutin Survival and functional status after resection of recurrent glioblastoma multiforme Neurosurgery 42 1998 709 720
10. N.A. Butowski, P.K. Sneed, and S.M. Chang Diagnosis and treatment of recurrent high-grade astrocytoma J Clin Oncol 24 2006 1273 1280 (Pubitemid 46622030)
11. A.D. Norden, G.S. Young, and K. Setayesh Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 2008 779 787
12. M. Bower, E.S. Newlands, and N.M. Bleehen Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemother Pharmacol 40 1997 484 488 (Pubitemid 27389289)
13. W.K. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 2000 588 593 (Pubitemid 30636298)
14. A.A. Brandes, M. Ermani, and U. Basso Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study Ann Oncol 12 2001 255 257 (Pubitemid 32223878)
15. M. Brada, K. Hoang-Xuan, and R. Rampling Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 2001 259 266 (Pubitemid 32223879)
16. I.K. Mellinghoff, A.B. Lassman, and P.Y. Wen Signal transduction inhibitors and antiangiogenic therapies for malignant glioma Glia 59 2011 1205 1212
17. W. Wick, M. Platten, and M. Weller New (alternative) temozolomide regimens for the treatment of glioma Neurooncol 11 2009 69 79
18. H.B. Newton, L. Junck, and J. Bromberg Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure Neurology 40 1990 1743 1746 (Pubitemid 20383143)
19. W.T. Couldwell, D.R. Hinton, and A.A. Surnock Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen Clin Cancer Res 2 1996 619 622
20. A. Wick, C. Pascher, and W. Wick Rechallenge with temozolomide in patients with recurrent gliomas J Neurol 256 2009 734 741
21. J. Tuettenberg, R. Grobholz, and T. Korn Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme J Cancer Res Clin Oncol 131 2005 31 40
22. L. Liu, P. Taverna, and C.M. Whitacre Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents Clin Cancer Res 5 1999 2908 2917 (Pubitemid 29493970)
23. R.J. Hansen, R. Nagasubramanian, S.M. Delaney, L.D. Samson, and M.E. Dolan Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice Carcinogenesis 28 2007 1111 1116 (Pubitemid 47072198)
24. A.E. Pegg Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents Cancer Res 50 1990 6119 6129 (Pubitemid 20323662)
25. M. Weller, R. Stupp, and G. Reifenberger MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 2010 39 51
26. M.E. Hegi, L. Liu, and J.G. Herman Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26 2008 4189 4199
27. F. Bertolini, S. Paul, and P. Mancuso Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63 2003 4342 4346 (Pubitemid 36951001)
28. P. Hau, D. Koch, and T. Hundsberger Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology 68 2007 688 690 (Pubitemid 46667817)
29. A.W. Tolcher, S.L. Gerson, and L. Denis Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 2003 1004 1011 (Pubitemid 36560766)
30. A.A. Brandes, A. Tosoni, and G. Cavallo Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 2006 1155 1160 (Pubitemid 44658477)
31. A.A. Brandes, M. Ermani, and U. Basso Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study Oncology 63 2002 38 41 (Pubitemid 34977935)
32. W. Wick, J.P. Steinbach, and W.M. Kuker One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma Neurology 62 2004 2113 2115 (Pubitemid 38738235)
33. A. Wick, J. Felsberg, and J.P. Steinbach Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 2007 3357 3361 (Pubitemid 47325623)
34. A. D'Amico, M. Gabbani, and S. Dall'oglio Protracted administration of low doses of temozolomide (TMZ) in the treatment of relapse glioblastoma (GBM) enhances the antitumor activity of this agent J Clin Oncol 24 Suppl 2006 Abstract 1572
35. E. Franceschi, A.M. Omuro, and A.B. Lassman Salvage temozolomide for prior temozolomide responders Cancer 104 2005 2473 2476 (Pubitemid 41691570)
36. H. Kurzen, S. Schmitt, and H. Naher Inhibition of angiogenesis by non-toxic doses of temozolomide Anticancer Drugs 14 2003 515 522 (Pubitemid 37083156)
37. J.R. Perry, P. Rizek, and R. Cashman Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 113 2008 2152 2157
38. J.R. Perry, K. Belanger, and W.P. Mason Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 2010 2051 2057
39. ClinicalTrials.gov Comparison of two dosing regimens of temozolomide in patients with progressive or recurrent glioblastoma (DIRECTOR) http://clinicaltrials.gov/ct2/show/NCT00941460 Accessed August 19, 2011
40. H.S. Friedman, T. Kerby, and H. Calvert Temozolomide and treatment of malignant glioma Clin Cancer Res 6 2000 2585 2597 (Pubitemid 30482092)
41. E.M. Gartner, A.M. Burger, and P.M. Lorusso Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future Cancer J 16 2010 83 90
42. J.D. Iglehart, and D.P. Silver Synthetic lethalitya new direction in cancer-drug development N Engl J Med 361 2009 189 191
43. S.K. Sandhu, T.A. Yap, and J.S. de Bono Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur J Cancer 46 2010 9 20
44. A. Mangerich, and A. Burkle How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation Int J Cancer 128 2011 251 265
45. C.L. Cheng, S.P. Johnson, and S.T. Keir Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol Cancer Ther 4 2005 1364 1368
46. S.J. Miknyoczki, S. Jones-Bolin, and S. Pritchard Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor Mol Cancer Ther 2 2003 371 382
47. L. Tentori, C. Leonetti, and M. Scarsella Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 2003 5370 5379 (Pubitemid 37413592)
48. C.K. Donawho, Y. Luo, and T.D. Penning ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2007 2728 2737 (Pubitemid 46795129)
49. M.J. Clarke, E.A. Mulligan, and P.T. Grogan Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines Mol Cancer Ther 8 2009 407 414
50. ClinicalTrials.gov ABT-888 and temozolomide in treating patients with recurrent glioblastoma http://clinicaltrials.gov/ct2/show/NCT01026493 Accessed August 19, 2011
51. J.O. Blakeley, X. Ye, and S.A. Grossman Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma J Clin Oncol.w 28 Suppl 2010 Abstract 2012
52. F.A. Dungey, D.A. Loser, and A.J. Chalmers Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential Int J Radiat Oncol Biol Phys 72 2008 1188 1197
53. ClinicalTrials.gov Olaparib and temozolomide in treating patients with relapsed glioblastoma http://clinicaltrials.gov/ct2/show/NCT01390571 Accessed August 19, 2011
54. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
55. O.O. Kanu, B. Hughes, and C. Di Glioblastoma multiforme oncogenomics and signaling pathways Clin Med Oncol 3 2009 39 52
56. B. Hasselbalch, J.G. Eriksen, and H. Broholm Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan APMIS 118 2010 585 594
57. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003 (Pubitemid 40349502)
58. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
59. H. Colman, L. Zhang, and E.P. Sulman A multigene predictor of outcome in glioblastoma Neurooncol 12 2010 49 57
60. W.A. Freije, F.E. Castro-Vargas, and Z. Fang Gene expression profiling of gliomas strongly predicts survival Cancer Res 64 2004 6503 6510 (Pubitemid 39297907)
61. I.K. Mellinghoff, M.Y. Wang, and I. Vivanco Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2005 2012 2024 (Pubitemid 41609094)
62. J.M. Nigro, A. Misra, and L. Zhang Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma Cancer Res 65 2005 1678 1686 (Pubitemid 40478592)
63. H.S. Phillips, S. Kharbanda, and R. Chen Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173 (Pubitemid 43357943)
64. R.G. Verhaak, K.A. Hoadley, and E. Purdom Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
65. S.M. Chang, K.R. Lamborn, and J.G. Kuhn Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium Neurooncol 10 2008 631 642
66. M.R. Gilbert, J. Gonzalez, and K. Hunter A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma Neurooncol 12 2010 1167 1172
67. F.A. McAlister, S.E. Straus, and D.L. Sackett Analysis and reporting of factorial trials: a systematic review JAMA 289 2003 2545 2553 (Pubitemid 37430156)
68. Biobusiness Briefs: Trial Watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment Nat Rev Drug Discovery 9 2010 423
69. ClinicalTrials.gov Bevacizumab versus bevacizumab plus vorinostat in adults with recurrent glioblastoma http://clinicaltrials.gov/ct2/show/ NCT01266031 Accessed August 19, 2011
70. ClinicalTrials.gov Phase I/II vorinostat, erlotinib and temozolomide for recurrent glioblastoma multiforme (GBM) http://clinicaltrials.gov/ct2/show/ NCT01110876 Accessed August 19, 2011
71. A.D. Norden, J. Drappatz, and P.Y. Wen Antiangiogenic therapies for high-grade glioma Nat Rev Neurol 5 2009 610 620
72. M. Onishi, T. Ichikawa, and K. Kurozumi Angiogenesis and invasion in glioma Brain Tumor Pathol 28 2011 13 24
73. N.O. Schmidt, M. Westphal, and C. Hagel Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis Int J Cancer 84 1999 10 18 (Pubitemid 29059101)
74. M.C. Chamberlain Bevacizumab for the treatment of recurrent glioblastoma Clin Med Insights Oncol 5 2011 117 129
75. A. Salmaggi, M. Eoli, and S. Frigerio Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma J Neurooncol 62 2003 297 303 (Pubitemid 36591966)
76. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
77. T.N. Kreisl, L. Kim, and K. Moore Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
78. FDA Briefing Document Oncology Drug Advisory Committee Meeting, March 31, 2009 www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4427b1-01-FDA.pdf
79. M.C. Chamberlain, and S.K. Johnston Salvage therapy with single agent bevacizumab for recurrent glioblastoma J Neurooncol 96 2010 259 269
80. A.D. Norden, J. Drappatz, and A. Muzikansky An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma J Neurooncol 92 2009 149 155
81. A. Narayana, P. Kelly, and J. Golfinos Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival J Neurosurg 110 2009 173 180
82. M.K. Nicholas, R.V. Lukas, and S. Chmura Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges Semin Oncol 38 2011 243 253
83. T.T. Batchelor, D.G. Duda, and E. di Tomaso Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2010 2817 2823
84. J.F. de Groot, K.R. Lamborn, and S.M. Chang Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study J Clin Oncol 29 2011 2689 2695
85. P.Y. Wen, M. Prados, and D. Schiff Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) J Clin Oncol 28 Suppl 2010 Abstract 2006
86. B.P. Eliceiri, and D.A. Cheresh The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development J Clin Invest 103 1999 1227 1230 (Pubitemid 29218291)
87. C.L. Gladson Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors J Neuropathol Exp Neurol 55 1996 1143 1149 (Pubitemid 26372791)
88. L. Bello, M. Francolini, and P. Marthyn Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery Neurosurgery 49 2001 380 389
89. S. Chatterjee, A. Matsumura, and J. Schradermeier Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents J Neurooncol 46 2000 135 144 (Pubitemid 30352620)
90. T.J. MacDonald, T. Taga, and H. Shimada Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist Neurosurgery 48 2001 151 157 (Pubitemid 32039837)
91. S. Yamada, X.Y. Bu, and V. Khankaldyyan Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice Neurosurgery 59 2006 1304 1312 (Pubitemid 44949775)
92. D.A. Reardon, K.L. Fink, and T. Mikkelsen Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 2008 5610 5617
93. K. Fink, T. Mikkelsen, and L.B. Nabors Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study J Clin Oncol 15 Suppl 2010 28: Abstract 2010
94. M.R. Gilbert, J. Kuhn, and K.R. Lamborn Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery J Neurooncol 2011 Jul 8[Epub ahead of print]
95. ClinicalTrials.gov Cilengitide and sunitinib malate in treating patients with advanced solid tumors or glioblastoma multiforme http://www.clinicaltrials. gov/ct2/show/NCT01122888 Accessed August 19, 2011
96. ClinicalTrials.gov Cediranib maleate and cilengitide in treating patients with progressive or recurrent glioblastoma http://www.clinicaltrials.gov/ct2/ show/NCT00979862 Accessed August 19, 2011
97. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
98. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology Working Group J Clin Oncol 28 2010 1963 1972
99. M.J. van den Bent, A.A. Brandes, and R. Rampling Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 2009 1268 1274
100. J.N. Rich, D.A. Reardon, and T. Peery Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 2004 133 142 (Pubitemid 41095125)
101. E. Franceschi, G. Cavallo, and S. Lonardi Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Br J Cancer 96 2007 1047 1051 (Pubitemid 46608313)
102. E. Raymond, A.A. Brandes, and C. Dittrich Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 2008 4659 4665
103. F.M. Iwamoto, K.R. Lamborn, and H.I. Robins Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) Neurooncol 12 2010 855 861
104. E. Galanis, K.A. Jaeckle, and M.J. Maurer Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study J Clin Oncol 27 2009 2052 2058
105. T.F. Cloughesy, P.Y. Wen, and H.I. Robins Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study J Clin Oncol 24 2006 3651 3656 (Pubitemid 46630540)
106. E. Galanis, J.C. Buckner, and M.J. Maurer Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study J Clin Oncol 23 2005 5294 5304 (Pubitemid 46206983)
107. S.M. Chang, P. Wen, and T. Cloughesy Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 23 2005 357 361 (Pubitemid 40980358)
108. W. Wick, V.K. Puduvalli, and M.C. Chamberlain Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J Clin Oncol 28 2010 1168 1174
109. T.N. Kreisl, S. Kotliarova, and J.A. Butman A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas Neurooncol 12 2010 181 189
110. W. Wick, M. Weller, and M. Weiler Pathway inhibition: emerging molecular targets for treating glioblastoma Neurooncol 13 2011 566 579
111. D.A. Reardon, A. Desjardins, and J.J. Vredenburgh Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study Br J Cancer 101 2009 1986 1994
112. R. Maron, J. Vredenburgh, and A. Desjardins Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM) J Clin Oncol 26 Suppl 2008 Abstract 2074
113. D.A. Reardon, A. Desjardins, and K.B. Peters Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy Cancer 2011 May 16 [Epub ahead of print]
114. B. Hasselbalch, U. Lassen, and S. Hansen Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial Neurooncol 12 2010 508 516
115. F. Stockhammer, M. Misch, and A. Koch Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma J Neurooncol 100 2010 407 415
116. T. Walbert, M.R. Gilbert, and M.D. Groves Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma J Neurooncol 102 2011 273 280
117. P.H. Gutin, F.M. Iwamoto, and K. Beal Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 2009 156 163